Bharat Immunologicals & Biologicals 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Dhananjay Tiwary

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	1.2yrs
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	2.8yrs

최근 관리 업데이트

Recent updates

CEO

Dhananjay Tiwary

1.2yrs

테뉴어

Dr. Dhananjay Kumar Tiwary is MD & Director of Bharat Immunologicals & Biologicals Corporation Limited from September 18, 2023.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Dhananjay Tiwary	MD & Director	1.2yrs	데이터 없음	데이터 없음
Sudhanshu Vrati	Independent Chairman	no data	₹10.00k	데이터 없음
Alka Sharma	Independent Director	no data	데이터 없음	0% ₹ 0
Mohd. Aslam	Independent Director	no data	데이터 없음	데이터 없음
Madhu Dikshit	Independent Director	5.4yrs	₹10.00k	데이터 없음
Pankaj Kumar	Independent Director	2.8yrs	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

경험이 풍부한 이사회: 524663 의 이사회는 경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Bharat Immunologicals & Biologicals 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Bharat Immunologicals & Biologicals Corporation Limited, Annual General Meeting, Dec 29, 2023

Bharat Immunologicals & Biologicals Corporation Limited, Annual General Meeting, Dec 30, 2020

Recent updates

Now 23% undervalued after recent price drop

New minor risk - Financial data availability

Now 20% undervalued

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Now 23% undervalued

Now 21% undervalued

Bharat Immunologicals & Biologicals Corporation Limited, Annual General Meeting, Dec 29, 2023

Second quarter 2024 earnings released: ₹1.14 loss per share (vs ₹0.71 loss in 2Q 2023)

Bharat Immunologicals & Biologicals Corporation Limited to Report Q2, 2024 Results on Oct 31, 2023

Now 20% undervalued

New minor risk - Financial data availability

Third quarter 2023 earnings released: ₹1.08 loss per share (vs ₹0.08 loss in 3Q 2022)

Second quarter 2023 earnings released: ₹0.71 loss per share (vs ₹2.17 loss in 2Q 2022)

First quarter 2023 earnings released: ₹1.16 loss per share (vs ₹0.45 profit in 1Q 2022)

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: ₹2.17 loss per share (vs ₹0.90 loss in 2Q 2021)

Full year 2021 earnings released: ₹3.03 loss per share (vs ₹2.37 loss in FY 2020)

Third quarter 2021 earnings released: ₹0.44 loss per share (vs ₹0.54 loss in 3Q 2020)

Second quarter 2021 earnings released: ₹0.90 loss per share

Bharat Immunologicals & Biologicals Corporation Limited, Annual General Meeting, Dec 30, 2020

New 90-day high: ₹37.60

New 90-day low: ₹23.35

First quarter earnings released

Full year earnings released - ₹2.36 loss per share

CEO

테뉴어

이사회 구성원

평균 재임 기간